MIT Launches $38M Wearable Patch Detecting Heart Disease Early

An -led team will develop PYTHIA, a non-invasive, wearable patch to measure biomarkers for heart disease and sepsis, with an up to $38 million award from ARPA-H. The patch could help clinicians [···]

Proposes a deep-learning technology that separates brain signals into 'rhythms' and 'background signals' without compromising temporal resolution. - Improves gait prediction performance in [···]

The FDA accepted uniQure's AMT-130 application for Huntington's disease, granted priority review, and set a May 1, 2027, target decision date while approval remains uncertain.

A single suppressor tRNA therapy could treat multiple ultrarare diseases, potentially making drug development for these small populations commercially viab...

After a whirlwind third quarter that saw two FDA approvals but a major setback in Angelman syndrome, Ultragenyx is laying off staff for the second time this year. The California biopharma

Nov 3 (Reuters) - Nurix Therapeutics said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential [···]

/PRNewswire/ - Scope Health, Inc., an international healthcare company dedicated to the management of ocular surface disease, today announced the launch of...

The FDA appears likely to hold an advisory committee for UniQure's closely watched Huntington's disease gene therapy. Elsewhere, a biotech's share price was cut in half following a regulatory [···]

A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.

In statin-naive patients with stable coronary artery disease, a more intensive lipid-lowering therapy is associated with greater reductions in volumes of total and noncalcified plaques.

uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately [···]

uniQure (QURE) stock drops 2.98% to $24.09 despite FDA Priority Review for its Huntington's disease gene therapy, with a May 2027 decision date.

Plus news about AbbVie, Gilead and Tiziana Life Sciences. FDA gives uniQure a review date and adcomm: The agency will decide whether or not to approve UniQure's high-profile Huntington's disease [···]

Dutch gene therapy developer uniQure today announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec [···]

Nov 2 (Reuters) - Dutch gene therapy developer uniQure said on Monday the US FDA had accepted its application for its Huntington's disease treatment and would decide on the drug by May 1, 2027. [···]

Western University spinout raises $35-million after generating promising pre-clinical results

Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.

Patients with autoimmune rheumatic conditions demonstrated a 1.5-fold increased risk for long COVID after infection compared with controls, according to data published in Arthritis & [···]

US biotech companies Bambusa Therapeutics and Aspen Neuroscience have priced initial public offerings (IPOs) totaling $309.5 million to fund development of experimental treatments for inflammatory [···]

The FDA granted accelerated approval to Inovio's Voceryq for adults with recurrent respiratory papillomatosis, a rare HPV-related airway disease requiring repeated surgeries.